A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 241-246

  Knox, Jennifer J ^a   Qin, Rui ^b   Strosberg, Jonathan R ^c   Tan, Benjamin ^d   Kaubisch, Andreas ^e   El Khoueiry, Anthony B ^f   Bekaii Saab, Tanios S ^g   Rousey, Steven R ^h   Chen, Helen X ⁱ   Erlichman, Charles ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h Metro Minnesota CCOP   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Hepatocellular carcinoma; Phase II; Temsirolimus

Indexed keywords

ALPHA FETOPROTEIN; BEVACIZUMAB; CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS; TRIACYLGLYCEROL; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; RAPAMYCIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALCOHOL LIVER CIRRHOSIS; ANEMIA; ANOREXIA; ANUS FISTULA; ANXIETY DISORDER; ARTICLE; BLEEDING; BONE METASTASIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILD PUGH SCORE; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; COUGHING; CYTOPENIA; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG HEMORRHAGE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RECTUM FISTULA; SIDE EFFECT; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; UPPER GASTROINTESTINAL BLEEDING; VISCERAL METASTASIS; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84922079748     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0169-3     Document Type: Article

References (20)

1. Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23(13):2892-9
2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340(10):745-50
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6):1752-63
4. Simonetti RG, Liberati A, Angiolini C et al (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8(2):117-36
5. Thomas MB, Abbruzzese JL (2005) Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23(31):8093-8108
6. Li X, Tang Z, Zhou G (1998) Expression of vascular endothelial growth factor correlates with invasion and metastatis of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 20:12-4
7. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-90
8. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34
9. Siegel AB, Cohen EI, Ocean A et al (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26(18):2992-8
10. Lang SA, Moser C, Fichnter-Feigl S et al (2009) Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49(2):523-32
11. Huynh H, Chow PK, Palanisamy N et al (2008) Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 49(1):52-60
12. Zhu AX, Kudo M, Assenat E et al (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312(1):57-67
13. Stephan ES, Datta K, Wang E et al (2004) Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 10(20):6993-7000
14. Merchan JR, Pitot HC, Qin R et al., Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma. J Clin Oncol 29: 2011 (suppl; abstr 4548)
15. Sarantopoulous J, Lenz H, LoRusso E et al. Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group Study. J Clin Oncol 29:2011 (suppl abstr 3072)
16. Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27(6):843-850
17. Hsu CH, Kang YK, Yang TS et al (2013) Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinaom: a multicenter phase II study. Oncology 85(1):44-52
18. Abou-Alfa GK, Johnson P, Knox JJ et al (2010) Doxorubicin plus sorafenib vs Doxorubicin alone in patients with advanced hepatocellular carcinoma, a randomized trial. JAMA 304(19):2154-2160
19. Llovet JM, Decaens T, Raoul JL et al (2012) Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. J Hepatol 56(2):S549
20. Kelley RK, Nimeiri HS, Munster PN et al (2013) Temsirolimus combined with sorafenib in hepatocellulat carcinoma: a phase I dose finding trial with pharmacokinetic and biomarker correlates. Ann Oncol 24(7):1900-7